Ab Immunotherapy is a promising therapeutic approach for Alzheimer's disease. Preclinical studies demonstrate that plaque prevention is possible; however, the more relevant therapeutic removal of existing plaque has proven elusive. Monoclonal antibodies in development target both soluble and insoluble Ab peptide. We hypothesized that antibody specificity for deposited plaque was critical for plaque removal since soluble Ab peptide would block recognition of deposited forms. We developed a plaque-specific antibody that targets a modified Ab peptide (Ab p3-42 ), which showed robust clearance of pre-existing plaque without causing microhemorrhage. Interestingly, a comparator N-terminal Ab antibody 3D6, which binds both soluble and insoluble Ab 1-42 , lacked efficacy for lowering existing plaque but manifested a significant microhemorrhage liability. Mechanistic studies suggested that the lack of efficacy for 3D6 was attributed to poor target engagement in plaques. These studies have profound implications for the development of therapeutic Ab antibodies for Alzheimer's disease.
INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by two hallmark pathologies, extracellular amyloid plaques and intracellular neurofibrillary tangles. Strong genetic and biochemical evidence highlights a central role of the amyloid pathway in the pathogenesis of AD (Hardy and Selkoe, 2002) . The central theme of the ''amyloid hypothesis'' is that amyloid deposition is the causative factor for the initiation of the neurodegeneration cascade, which includes inflammation, gliosis, neuronal damage, synaptic loss, and cell loss. Although the exact neurotoxic moiety remains speculative (monomer, soluble oligomer, or fibril), the neuropathological findings indicate that neurodegeneration of the AD type occur after initial amyloid deposition. Since monomer Ab and fibrils are in equilibrium (DeMattos et al., 2002; Tseng et al., 1999) , the deposited plaque probably acts as a reservoir for soluble Ab, and thus eliminating the deposits would have a multifold benefit through the reduced levels of all possible toxic forms of Ab (monomer, oligomer, and fibril). Although most of the early onset familial forms of AD arise due to mutations that alter the synthesis of Ab to favor increased levels of the Ab 42 peptide, the vast majority of cases of idiopathic AD (>95%) are thought to be due to faulty clearance of the peptide and/or deposit (Saido, 1998) .
Immunotherapy is a promising therapeutic approach focused on using antibodies to facilitate clearance of the Ab peptide. Three main mechanisms of action for Ab immunotherapy have been postulated: soluble equilibrium, phagocytosis, or blockade of amyloid seeding. The soluble equilibrium mechanism is based upon antibodies neutralizing soluble Ab and shifting the equilibrium to favor dissolution (DeMattos et al., 2001 ).This mechanism of action is proposed to take place in both the periphery and central compartments (DeMattos et al., 2001; Yamada et al., 2009) . The phagocytosis mechanism requires antibodies gaining access to the CNS, where they engage deposited amyloid (opsonization) and facilitate microglial-mediated phagocytosis of the plaque (Bard et al., 2000) . Finally, others have postulated that prevention of amyloid deposition may be due to antibodies binding to early amyloid seeds at a point in the cascade when these species are present at low abundance, thus preventing amyloid propagation (Golde, 2003) . Thus far, investigators have focused mostly on N-terminal antibodies, which can bind either soluble or insoluble forms of Ab, for targeting plaque (Pul et al., 2011) . Prior studies have shown that both active and passive immunotherapy are effective in reducing amyloid deposition in transgenic APP mice when performed as a preventative measure; however, when these approaches are performed in aged transgenic mice with pre-existing deposits, they showed diminished (Levites et al., 2006) or no (Das et al., 2001 ) efficacy. We hypothesized that the inability of the N-terminal antibodies to remove existing plaque was due to antibody saturation with soluble Ab upon entering the CNS. Thus, nonselective antibodies will lack sufficient target engagement of deposited plaque and will not efficiently opsonize the intended target.
In order to test our hypothesis, we developed an antibody that selectively targets deposited plaque in AD brain. The deposits found in AD are comprised of a heterogeneous mixture of Ab peptides . Although the majority of the Ab peptides end in the 42nd amino acid, there is an extraordinary amount of heterogeneity at the amino terminus. One previously identified truncation is the Ab p3-42 Kuo et al., 1997; Saido et al., 1995) . The Ab p3-42 peptide arises due to amino-terminal proteases trimming the first two amino acids from the peptide, followed by cyclization of the functional group to form a pyrol ring at the amino terminus (pyroglutamate). This latter modification can occur spontaneously or by the action of glutaminyl cyclase (Chelius et al., 2006; Cynis et al., 2006) . Early studies demonstrated that the Ab p3-42 peptide accumulates early in the deposition cascade Saido et al., 1995) and the biophysical properties of the Ab p3-42 highlighted the aggressive aggregation properties of the peptide Schlenzig et al., 2009 ). Since no published study reported detectable Ab p3-42 peptide in a physiological fluid (i.e., CSF or plasma), this modified Ab peptide is probably plaque specific and thus an ideal target for immunotherapy.
We generated and engineered high-affinity murine monoclonal antibodies specific for Ab p3-x with either minimal (mE8-IgG1) or maximal (mE8-IgG2a) effector function. These antibodies robustly labeled deposited plaque in both AD and PDAPP brain sections and led to a significant reduction of deposited Ab in an ex vivo phagocytosis assay. Therapeutic plaque-lowering studies performed with the anti-Ab p3-42 antibodies in extremely aged PDAPP mice (23 to 26 months of age) demonstrated that mE8 on either maximal or minimal effector function significantly lowered deposited Ab, whereas mice treated with the N-terminal antibody 3D6 (mIgG2b), which binds both soluble and insoluble Ab, lacked efficacy. The underlying mechanism of action responsible for these contrasting results was identified as a differential target engagement for the antibodies; the Ab p3-42 antibodies crossed the blood-brain barrier and bound to the deposited Ab, whereas the 3D6 antibody lacked plaque binding, a finding thought to be due to its saturation with soluble Ab in brain. Importantly, microhemorrhage analyses demonstrated that the Ab p3-42 antibodies did not increase this adverse event, whereas mice treated with 3D6 had extensive microbleeds. These mechanistic findings have important implications for the interpretation of current clinical studies and the development of second generation antibodies for AD immunotherapy.
RESULTS
Prevention and Therapeutic Immunotherapy with an N-terminally Directed Ab Antibody that Recognizes All Forms of Ab Plaque-lowering studies were performed in PDAPP transgenic mice to investigate the ability of an amino-terminally directed Ab antibody to either prevent or lower existing amyloid deposits. The monoclonal antibody 3D6, the murine equivalent of bapineuzumab, binds to both soluble and insoluble Ab at the extreme amino terminus (Ab 1-5 ) with an affinity of $3-5 nM (k off $2 3 10 À4 /s at 25 C). Two study paradigms were investigated, either plaque prevention (ages 9 to 12 months) or a therapeutic study exploring attenuation of ongoing deposition or clearance of plaques (ages 18 to 21 months). For both studies, a group of PDAPP mice were sacrificed at study initiation (time zero) to determine the extent of existing pathology prior to dosing. PDAPP transgenic mice were treated for 3 months with weekly injections of 3D6 at 12.5 mg/kg ($500 mg) or vehicle (PBS). An analysis of the 9-month-old PDAPP mice treated for 3 months with 3D6 demonstrated a significant prevention of Ab deposition in hippocampus (40%, p < 0.0161, Figure 1A ) and cortex (69%, p < 0.0001, Figure 1B ). In contrast, the aged PDAPP mice treated from 18 to 21 months showed no effect on levels of existing deposited Ab in either the hippocampus (p = 0.7441, Figure 1C ) or cortex (p = 0.5959, Figure 1D ). A comparison of the time zero (18 months) versus the vehicle-treated (21 months) animals demonstrates that deposition had reached a plaque plateau in Chronic administration of the N-terminal antibody 3D6 significantly lowers plaque deposition in PDAPP mice when treatment is initiated at 9 months of age (prevention dosing) but fails to alter deposition when initiated at 18 months of age (therapeutic dosing). Nine-month-old PDAPP mice were treated for 3 months with weekly intraperitoneal injections of 12.5 mg/kg of 3D6 (n = 18) or vehicle control (n = 22 Eighteen-month-old PDAPP mice were treated for 3 months with weekly intraperitoneal injections of 12.5 mg/kg of 3D6 (n = 22) or vehicle control (n = 21). Time zero group (18 months old, n = 23) was sacrificed at the onset of the study. (C) In hippocampus, very little further deposition occurred during the 3 months of treatment (9%) and 3D6 treatment had no significant effect on plaque lowering. (D) The Ab 1-42 in cortex did increase between 18 and 21 months (189%); however, 3D6 treatment had no significant effect at this age. The error bars represent SEM.
hippocampus prior to the initiation of dosing, a finding that suggests that the deposition in the aged PDAPP (>18 months) may be representative of a similar plaque plateau implied by cross-sectional amyloid PET studies in cohorts of patients with early to midstage AD. PDAPP cortical Ab deposition is significantly lower than hippocampus and the rate of accumulation in the aged PDAPP mice between 18 and 21 months increased $2-fold, thereby suggesting a delay in reaching the plaque plateau in this tissue. These plaque-lowering studies confirm previously published literature showing beneficial effects of Ab immunotherapy when used for prevention of amyloid deposition (Bard et al., 2000 (Bard et al., , 2003 but not for clearance of established deposits.
Generation and Ex Vivo Characterization of Anti-Ab p3-42 Antibodies Previous studies demonstrated that the modified Ab p3-42 peptide accumulates early in the deposition cascade Saido et al., 1995) and probably was specific for plaque (i.e., no soluble peptide found in physiological fluids). We immunized mice with the Ab p3-42 peptide and subsequently screened clones for Ab p3-x binding and counterscreened against Ab . A low-affinity Ab p3-42 monoclonal antibody was affinity matured to yield the highaffinity (140 pM) anti-Ab p3-x antibody mE8 (k off < 1 3 10 À5 /s at 25 C). Characterization of the binding properties of mE8 demonstrated that it specifically recognized the modified amino terminus of Ab p3-x in that it does not recognize full-length Ab or unmodified Ab 3-x (see Figure S1 available online). In order to evaluate the impact of effector function on in vivo plaque clearance, mE8 was made in both mouse IgG1 (minimal effector function) and IgG2a (maximal effector function) isotypes. The affinity-matured mE8 was first used to investigate levels of the Ab p3-42 peptide in PDAPP and AD brain lysates. ELISA analyses demonstrated that low levels of the Ab p3-42 peptide could be detected in both PDAPP and AD brains (Figure 2A) . Interestingly, the prevalence of the Ab p3-42 peptide was quite low ($0.6%) with respect to the overall amount of Ab42 deposited in these brains ( Figure 2B ). The analyses also showed an age-dependent accumulation of Ab p3-42 peptide in PDAPP brains that increased 47-fold between 12 and 23 months of age ( Figure 2A ). The similar prevalence of Ab p3-42 in AD patients and PDAPP mouse brains demonstrates that our transgenic model recapitulates the generation of this neuropathological target.
Immunohistochemical analyses were performed with antiAb p3-x antibodies in order to determine whether the epitope is accessible in aged PDAPP and AD brain sections. Robust Ab staining was observed in brain sections from a 24-month-old PDAPP mouse with 3D6 ( Figure 2C ) and more discrete staining was observed for the mE8 antibody ( Figure 2D ). Histological analyses performed on fresh-frozen AD brain resulted in similar staining between the 3D6 and mE8 antibodies, where again the labeling was more intense and widespread for the 3D6 antibody ( Figures 2E and 2F ). We next investigated whether the relatively low levels of the Ab p3-42 antigen would be sufficient to enable opsonization and Fc receptor-mediated phagocytosis. Ex vivo phagocytosis studies were performed with exogenously added Ab antibodies preincubated with AD brain sections that were subsequently treated with primary murine microglial cells ( Figure 2G ). The following murine Ab antibodies were investigated: 3D6 (anti-Ab 1-x , IgG2b), mE8 (anti-Ab p3-x , IgG1), mE8 (anti-Ab p3-x , IgG2a), 21F12 (anti-Ab x-42 , IgG1), 2G3 (anti-Ab x-40 , IgG1), and a murine control antibody (IgG2b, same effector function as 3D6). Note that the antibodies 21F12 and 2G3 bind deposited Ab quite poorly even though they robustly bind soluble Ab, a result likely due to epitope shielding that occurs once the Ab peptide is incorporated into the fibrils. Analysis of the remaining Ab 1-42 present in the tissue sections demonstrated that the 3D6 and mE8 (minimal or maximal effector function) aminoterminal antibodies significantly facilitated clearance of deposited plaque (p < 0.001). The Ab p3-x antibody with maximal effector function (mE8, IgG2a) cleared significantly (p < 0.001) more plaque than the Ab p3-x antibody with minimal effector function (mE8, IgG1). The control antibodies (21F12, 2G3, or control murine IgG2b), which lack the ability to bind the target, did not alter Ab clearance relative to the microglia cells alone. These results demonstrate that exogenous addition of the aminoterminal antibodies 3D6 and mE8 (minimal or maximal effector function) facilitated the targeting of microglia to the AD plaque. Interestingly, the ability of the amino-terminal antibody 3D6 to opsonize the plaque was no greater than the Ab p3-x antibodies, even though the antigen for 3D6 is significantly more abundant. Thus, targeting even minor components of the AD plaque is sufficient to drive microglial recognition and phagocytic clearance.
In Vivo Plaque-Lowering Studies: Therapeutic Study The ability of the murine anti-Ab p3-x antibodies with minimum (IgG1) and maximum (IgG2a) effector function to lower existing plaque was investigated in PDAPP mice. We performed a therapeutic plaque-lowering study in 23-to 24-month-old PDAPP mice with the following antibodies: negative control antibody (IgG2a), 3D6, mE8-IgG1, and mE8-IgG2a. Aged PDAPP mice were injected intraperitoneally with 12.5 mg/kg of each antibody weekly for 3 months. A time zero group of mice was necropsied at the beginning of the study in order to determine the initial plaque load at $24.5 months of age. Analysis of the hippocampal guanidine lysates from the time zero and antibody control (26 to 27 months old) cohorts showed a nonsignificant increase in deposited Ab 42 , thereby demonstrating that the brains of the PDAPP mice were at the plaque plateau ( Figure 3A ). Similar to our previous studies, treatment with the 3D6 antibody had no effect on amyloid levels in hippocampal lysates. In contrast, treatment with either Ab p3-x antibody, minimal or maximal effector function, resulted in significant Ab lowering as compared to the IgG control antibody (p < 0.01 and p < 0.001, respectively). The mE8-IgG1 and mE8-IgG2a lowered the Ab 42 by $38% and $53%, respectively. The Ab p3-x antibody with maximal effector function trended to being more efficacious than the minimal effector function antibody; however, this difference did not reach statistical significance. Importantly, the mE8-IgG2a antibody significantly lowered Ab 42 by $30% in the hippocampus as compared to the time zero mice (t test; p < 0.0066), thus demonstrating clearance of existing Ab deposits. The analyses of the cortical guanidine lysates yielded very similar outcomes with the exception that only the mE8-IgG2a with maximal effector function significantly decreased Ab 42 deposition ( Figure 3B ). ELISA analysis for plasma Ab40 and Ab42 revealed significantly elevated levels in 3D6-treated mice but no difference in the mE8-or control-treated mice ( Figures 3C and 3D ), which probably reflects the plaque-specific nature of Ab p3-x and the resultant low levels of this species in plasma. Analysis of the plasma IgG levels at the conclusion of the study showed similar mean levels between the 3D6, mE8-IgG1, and mE8-IgG2a dose groups ( Figure 3E ). Ab-lowering effectiveness was also investigated by histological end points. Morphological differences in the deposited plaque were observed in the animals treated with the Ab p3-x antibodies when brain sections were immunostained with multiple anti-Ab antibodies ( Figure 4A ). Animals treated with mE8-IgG2a consistently had areas of plaque deposition in the CA1 and CA3 regions that histologically appeared blurred and less defined; a similar but less dramatic effect was observed in mE8-IgG1-treated animals. However, an analysis of the percent area of the hippocampus covered by Ab immunostaining showed no significant difference among the treatment groups ( Figure 4B ). Likewise, analysis of the total amyloid load or microglia counts revealed no significant treatment effects (Figures S2 and S3) . Note that the PDAPP transgenic model mainly develops diffuse plaque. Thus, in this model, the anti-Ab p3-x antibodies predominantly reduced Ab as pre-existing diffuse plaque.
The Ab p3-x antibody-mediated clearance of existing plaque was highly repeatable. Since plaque-lowering studies have proven to be challenging to repeat in transgenic mice, we performed an additional dose-response study with our mE8 antibody. Sixteen-month-old PDAPP mice were injected subcutaneously weekly for 6 months with 1.5, 4, or 12.5 mg/kg of mE8-IgG2a or 12.5 mg/kg of the control antibody. This study demonstrated that significant additional deposition occurred during the 6 months of antibody treatment, wherein the deposited Ab nearly doubled in hippocampus (p < 0.001, Figure 5A ) and tripled in cortex (p < 0.001, Figure 5B ). A significant dosedependent decrease in Ab 42 was observed for the mE8-IgG2a treatment in both hippocampus (p < 0.0001, Figure 5A ) and cortex (p < 0.0073, Figure 5B ). In hippocampus, the 4 and 12.5 mg/kg doses significantly lowered deposited Ab 42 by 31% (p < 0.001) and 39% (p < 0.001), respectively. The 1.5 mg/kg dose of mE8-IgG2a was a nonsignificant 15% lower. The analyses of the cortical lysates yielded very similar results, with the exception that the 4 mg/kg dose did not achieve significance. These results demonstrated that the anti-Ab p3-xmediated plaque lowering is robust and repeatable.
Ab p3-x mAb Reduces Deposited Amyloid without Inducing Microhemorrhage An additional histological study was performed on brain sections from the 3 month therapeutic study (Figure 4 ) to investigate Neuron Anti-Ab p3-42 Antibody for Alzheimer's Disease whether the mechanism of action of the anti-Ab p3-x antibodies that leads to plaque lowering in aged PDAPP mice would also result in an exacerbation of CAA-related microhemorrhage. We have previously demonstrated that chronic treatment with 3D6 significantly increases the incidence of microhemorrhage (Racke et al., 2005) . In this study, we again observed a dramatic increase in microhemorrhage with 3D6 treatment (p < 0.001) ( Figure 4C) . Significantly, the 3D6-dependent exacerbation of microhemorrhage occurred even in the absence of plaque lowering. In contrast, treatment with either mE8-IgG1 or mE8-IgG2a did not significantly increase microhemorrhage, even though these Ab p3-x antibodies were able to reduce deposited Ab. These results demonstrate that treatment with the Ab p3-x antibodies in aged PDAPP mice with maximal plaque loads was able to reduce existing deposited Ab without CAA-related microhemorrhage liability. A chronic study demonstrates that Ab p3-42 antibodies on either minimum or maximum effector function significantly lower existing plaque in aged PDAPP mice. PDAPP mice (23 to 24 months old) were treated for 3 months with weekly intraperitoneal injections of 12.5 mg/kg of the following antibodies: m3D6 (anti-Ab 1-x , IgG2b, n = 30), mE8-IgG1 (anti-Ab p3-x , n = 27), mE8-IgG2a (anti-Ab p3-x , n = 23), or control IgG2a (n = 27). A time zero group ($24.5 months old, n = 15) was sacrificed at the onset of the study. In Vivo Plaque-Lowering Studies: Prevention Study To investigate whether the Ab p3-x antibody mE8-IgG2a would be efficacious at preventing plaque deposition, we performed a study in 5.5-month-old PDAPP mice, an age before the initiation of Ab deposition, with the following antibodies: negative control antibody (IgG2a), 3D6, and mE8-IgG2a. A time zero group and an additional parallel untreated group of transgenic mice were incorporated in the study to determine the time course of deposition. As expected, the time zero animals (5.5 months of age) lacked deposited Ab 42 ( Figure 5C ). In hippocampus, a dramatic accumulation of deposited Ab42 occurred throughout the study period ($45-fold) with the majority depositing during the latter 2 months of the study ($80% between months 10.5 and 12.5). Consistent with previous reports for similar N-terminal antibodies, treatment with 3D6 resulted in a significant $68% decrease of hippocampal Ab 42 (p < 0.001) as compared to the control IgG, although levels were higher than the untreated animals sacrificed at 10.5 months of age. The mE8-IgG2a treatment resulted in a nonsignificant $30% decrease in Ab 42 as compared to the control IgG-treated mice. Similar results were observed in the cortical extracts from these mice (Figure 5D ). These results demonstrate that while the phagocytic mechanism of the Ab p3-x antibody is able to clear deposited Ab, it is less effective at preventing Ab 42 deposition in young PDAPP mice. In contrast, the N-terminal antibody 3D6, which binds soluble and insoluble Ab, reveals an opposite pattern of efficacy (no clearance of established plaque and strong prevention of deposition), thereby suggesting that the major mechanism of action for these two antibodies is different. 
Delineation of Mechanism of Action
We sought to determine the mechanism of action responsible for the differential effects on plaque lowering observed for the Ab p3-x and 3D6 antibodies by performing in vivo target engagement studies. Our original hypothesis was that antibodies such as 3D6, which binds to both soluble and insoluble Ab, would have decreased plaque-lowering ability relative to plaque-specific antibodies since the 3D6 antibody (or any other antibody that binds soluble Ab) would become saturated with soluble Ab prior to reaching the deposited plaque. Biotinylated 3D6, mE8, or control IgG were peripherally injected into aged PDAPP mice to histologically determine the amount of antibody crossing the bloodbrain barrier and binding to deposited Ab. The amount of target engagement was first evaluated in aged PDAPP mice receiving a single injection of the antibodies (40 mg/kg) and subsequently sacrificed 3 days later ( Figure 6A , top). Animals injected with 3D6 had plaque labeling that was limited to a narrow area along the hippocampal fissure, whereas mice injected with mE8 displayed robust plaque labeling throughout the hippocampus and cortical regions. We next performed a subchronic study wherein aged PDAPP mice received four antibody injections over 21 days and the animals were Neuron Anti-Ab p3-42 Antibody for Alzheimer's Disease evaluated 3 days after the last dose (day 24) (Figure 6A , bottom). Similar to the acute study, the mE8 antibody robustly engaged deposited plaque, whereas 3D6 engagement was limited to the hippocampal fissure. To distinguish whether repeat administration of the anti-Ab at high doses would result in greater target engagement, brain sections from a subgroup of animals from both studies (acute and subchronic, n = 3 to 4 per group) were evaluated. As shown in the figure insets, the repeat dosing of high concentrations of antibodies resulted in an increase in target engagement for 3D6 along the hippocampal fissure (p = 0.0111) and a nonsignificant increase in hippocampal target engagement for mE8. To better quantify the target engagement in hippocampus and cortex, a separate acute study was performed in aged PDAPP mice ( Figure 6B ). In both hippocampus and cortex, the Ab p3-x antibody mE8 engaged significantly more target than 3D6 (p = 0.0005, p = 0.0408, respectively). Target engagement for 3D6 was again limited to the hippocampal fissure area. A nontransgenic rat pharmacokinetic study was performed to investigate whether 3D6 and mE8 access the CNS to a similar degree ( Figure 6C ). Although the majority of the CSF IgG concentrations overlapped for the two antibodies, the mE8 did have slightly higher levels that reached significance (p = 0.034). The difference in CSF levels was driven by higher plasma exposures, as evidenced by no difference in the CSF:plasma ratio. Next, we investigated whether soluble Ab 1-40 could inhibit antibody binding to deposited plaque in a histological experiment (Figure 6D) . Ab antibodies were preincubated with increasing concentrations of soluble Ab 1-40 prior to performing histology on brain sections from an aged PDAPP mouse. Preincubation of mE8 with soluble Ab 1-40 had no effect on plaque binding, whereas the soluble Ab 1-40 in a concentration-dependent manner dramatically inhibited 3D6's ability to bind deposited Ab. Taken together, these results strongly suggest that the 3D6 antibody becomes saturated with soluble Ab in the CNS and thus can not engage the deposited Ab, whereas the plaque-specific Ab p3-x antibody mE8 robustly engages the deposited amyloid. Lastly, to investigate the mechanism of plaque clearance with anti-Ab p3-x antibodies, we examined brains at the conclusion of the 6 month chronic study in aged PDAPP for histological signs of phagocytosis. Consistent with a phagocytotic mechanism of action, confocal microscopy illustrates convergence of activated microglia with deposited Ab in the anti-Ab p3-x -treated ( Figure S3 ) but not in control IgG2a-treated PDAPP mice. These results imply that chronic treatment with Ab p3-x antibodies significantly decreases amyloid deposition in aged PDAPP mice in a manner that is at least partially dependent on effector function. Aged PDAPP mice treated with the anti-Ab p3-42 antibody demonstrate a dose-dependent reduction of plaque, whereas the same antibody failed to significantly prevent deposition in young PDAPP mice. PDAPP mice (16 months old) were treated for 6 months with weekly subcutaneous injections of mE8-IgG2a at the following doses: 12.5 mg/kg (n = 23), 4 mg/kg (n = 23), or 1.5 mg/kg (n = 21). A time zero group (16 months old, n = 30) was sacrificed at the onset of the study. (A) In hippocampus, PDAPP mice treated with the varying doses of mE8-IgG2a showed a significant dose-dependent decrease in deposited Ab 1-42 (p < 0.0001, ANOVA). Animals dosed with 4 and 12.5 mg/kg of mE8c had significantly lower deposited Ab 1-42 as compared to the control IgG2a-injected animals (p < 0.001, Tukey's post hoc).
(B) In cortex, a less significant dose-dependent decrease in deposited Ab 1-42 (p < 0.0073, ANOVA) was observed. Animals dosed with 12.5 mg/kg of mE8-IgG2a had significantly lower deposited Ab 1-42 as compared to the control IgG2a-injected animals (p < 0.05, Tukey's post hoc). A plaque prevention study was conducted wherein PDAPP mice ($5.5 months old) were treated for 7 months with weekly subcutaneous injections of 12.5 mg/kg of the following antibodies: m3D6 (anti-Ab 1-x , IgG2b, n = 29), mE8-IgG2a (antiAb p3-x , n = 29), and control IgG2a (n = 29). A time zero group (5.5 months old, n = 30) and an untreated group of PDAPP mice (10.5 months of age, n = 27) were sacrificed to follow the deposition of Ab 1-42 during the course of the study. (C) In hippocampus, PDAPP mice treated with 3D6 had a significant decrease in deposited Ab 1-42 at the conclusion of the study (68%; p < 0.001, Tukey's post hoc). Preventative treatment with mE8-IgG2a had a nonsignificant $30% lowering of deposited Ab 1-42 . (D) In cortex, similar plaque prevention was observed for mice treated with 3D6 (52%; p < 0.001, Tukey's post hoc), whereas mE8-IgG2a failed to significantly prevent deposition (21%). The error bars represent SEM.
DISCUSSION
Current clinical immunotherapy trials are generally thought to be an important test of the amyloid hypothesis. The available supporting evidence for each compound, both preclinical and clinical, provides an indication to what extent the clinical trials will have tested the amyloid hypothesis, as opposed to merely testing the individual therapeutic antibodies. Prior preclinical studies have shown that both active and passive immunotherapies were effective in lowering plaque in transgenic APP mice when performed as a preventative measure; however, when these approaches were performed as a therapeutic in aged transgenic mice, they lacked efficacy in terms of amyloid reduction (Das et al., 2001; Levites et al., 2006) . Moreover, prevention of amyloid deposition with antibodies to the N terminus of Ab was still observed in APP mice that lack FcRg, which is required for antibody-induced phagocytosis by microglia (Das et al., 2003) . This result implied that phagocytosis was not required for prevention of amyloid deposition by passive immunotherapy, at least with nonselective N-terminal anti-Abeta mAbs. Several possible explanations were postulated to account for the lack of efficacy in aged animals, including deposited target overwhelming small amounts of CSF IgG, altered plaque morphology resulting in antibody resistance, or senescence of the microglial phagocytotic machinery (Das et al., 2001) . Our studies with the N-terminal antibody 3D6, the murine equivalent of bapineuzumab, replicated the literature wherein 3D6 significantly prevented plaque deposition yet consistently failed to alter deposition when administered to mice with extensive pre-existing Ab plaque.
We hypothesized that the lack of antibody engagement with amyloid deposits (plaque binding and phagocytosis) was due to saturating levels of soluble Ab in the vicinity of plaques and the lack of target engagement was the key underlying mechanism hindering Ab clearance with N-terminal antibodies that bind both soluble and insoluble Ab. To circumvent the hypothesized antibody saturation effect, we developed antibodies that are highly selective for deposited plaque. Our initial biochemical characterization of AD and PDAPP brains revealed a low prevalence of our intended immunotherapeutic target (Ab p3-42 $0.6% Ab p3-x ) , and control IgG. The antibody in vivo target engagement (plaque binding) was assessed histologically (strepavidin-HRP followed by DAB) 72 hr after injection (acute treatment, top). A subchronic 3 week study was conducted with the same antibodies (40 mg/kg weekly, 4 total doses, n = 7 to 9 per group) and the target engagement and CSF:plasma ratio was evaluated as above (subchronic treatment, bottom). A subgroup from the acute and subchronic studies (n = 3 to 4 per group) were evaluated within the same histological run in order to determine the relative target engagement in hippocampus (shown in the figure insets). (B) To quantify the target engagement, six aged PDAPP mice received a single 40 mg/kg injection of biotinylated 3D6 or mE8 and the total area of plaque labeling in hippocampus and cortex was measured histologically (strepavidin-HRP followed by DAB). When normalized for each respective target, the anti-Ab p3-x mE8 antibody showed significantly more target engagement in hippocampus (p = 0.0005) and cortex (p = 0.0408). The error bars represent SEM. (C) A nontransgenic rat 24 hr PK study performed with biotinylated Ab antibodies 3D6 (anti-Ab 1-x ) and mE8 (anti-Ab p3-x ) showed a slight but significant difference in plasma (p = 0.0012) and CSF antibody levels (p = 0.034). No significant difference was observed in the CSF:plasma ratio. (D) Antibody binding specificity in the presence of increasing concentrations of soluble Ab 1-40 was determined histologically for 3D6 and mE8. Biotinylated antibodies (3 mg/ml) were preincubated with soluble Ab 1-40 (0, 0.5, 5.0, and 10 mg/ml) prior to performing immunohistochemistry on brain sections from aged PDAPP mice.
Neuron
Anti-Ab p3-42 Antibody for Alzheimer's Disease of all Ab peptides found in brain). Similar low levels of Ab p3-42 have been reported in AD brain by other groups (Schilling et al., 2008) . Subsequent histological analyses demonstrated that the Ab p3-42 peptide was well distributed among the majority of the plaques, thus presenting an effective target for opsonization, FcR engagement, and microglial phagocytosis.
In addition to the roles of epitope abundance and antibody affinity in triggering effector function, antibody isotype has also been shown to be critically important (Nimmerjahn and Ravetch, 2005) . Utilizing Ab p3-x antibodies with isotypes of varying effector potency, we demonstrated that robust clearance of existing plaque was in agreement with reported ability to engage activating Fc receptors. Additionally, the plaque-lowering ability of the Ab p3-x antibody was shown to be highly repeatable in a dose-response study. Differences were observed in the efficacy of plaque lowering between hippocampus and cortex for the anti-Ab p3-x antibodies that may be a result of the lower net levels of deposited Ab or possibly the delay in deposition in this tissue relative to hippocampus (and thus less modified Ab species). Interestingly, in contrast to 3D6 and other N-terminal antibodies, the Ab p3-x antibody failed to show significant plaque lowering when used as a preventative measure. We attribute this observation to the lack of modified Ab target in the young PDAPP mice during the course of treatment prior to amyloid formation and during initial deposition. Additionally, the lack of efficacy in the prevention paradigm for the anti-Ab p3-x antibody suggests that Ab p3-x is not the major nucleating species for initial plaque deposition. Since the Ab p3-42 peptide appears to be solely located in deposits (Bibl et al., 2012) , the only mechanism of action through which the Ab p3-x antibodies could lead to plaque lowering is through phagocytosis of existing plaque. Consistent with this mechanism, we observed that treatment with Ab p3-42 antibodies led to increased microglial colocalization with amyloid deposits in vivo. In regard to Ab deposition, one critical parameter that is different between AD patients and PDAPP mice is the overall amount of Ab deposited per unit time. Imaging studies with amyloid PET ligands have demonstrated that plaque accrual in AD patients is minimal after diagnosis (Ossenkoppele et al., 2012; Villemagne et al., 2011) , whereas PDAPP mice have robust deposition even during the plateau phase (i.e., the time frame after the logarithmic phase of deposition), in which the Ab levels can increase by more than 30% in as little as 3 months. Thus, plaque lowering in PDAPP mice probably represents a very high hurdle since the final ''net'' plaque lowering will be a function of clearance of pre-existing plaque in addition to the newly formed plaque during the course of the study.
The central tenant of our original hypothesis was that antibodies that bind both soluble and insoluble forms of Ab will become saturated in the CNS prior to reaching deposited Ab. The blood-brain barrier only allows $0.1% of peripheral antibody to gain access to the central compartment. Moreover, the CNS has $20-to 67-fold higher levels of soluble Ab relative to the periphery (Giedraitis et al., 2007; Mehta et al., 2001) . Studies performed by Maggio and colleagues have demonstrated first-order rate constants for soluble monomer Ab associations with plaque Tseng et al., 1999) . Since Ab can associate and dissociate from existing plaque, as deposition increases, it will correspondingly drive concentrations of soluble monomer Ab higher in the microenvironment. Indeed, these equilibriums were previously observed in PDAPP transgenic mice (DeMattos et al., 2002) . These findings suggest that as deposition increases, a dense cloud of soluble Ab envelopes the plaque and acts as a barrier to prevent plaque binding for any Ab antibody that binds to the soluble form (Figure 7) . A recent study utilizing microdialysis found decreased soluble Ab concentrations in ISF during the course of plaque deposition, a finding suggestive of plaque sequestration (Hong et al., 2011) . These seemingly contrasting results probably arise due to the measurement of soluble Ab in different locales; the microdialysis studies measure a macroenvironment, whereas the proposed increased soluble pool of Ab would be highly localized to the microenvironment of the plaque (i.e., microns). This hypothesis is consistent with a recent publication showing that soluble oligomeric Ab species are present at high concentrations in the immediate vicinity of amyloid plaques (Koffie et al., 2009 ). Additionally, enhanced plaque removal has been demonstrated with an N-terminal antibody similar to 3D6 in an inducible APP transgenic mouse model, wherein soluble Ab was genetically reduced (Wang et al., 2011) . In support of our hypothesis, the in vivo target engagement studies showed a near complete lack of plaque binding for 3D6, yet the plaque-specific Ab p3-x antibody showed widespread binding to amyloid deposits in the hippocampus and cortex. The same 3D6 antibody was successful in an ex vivo phagocytosis model in which exogenous antibody facilitated plaque removal; however, in this experimental paradigm, high levels of antibody (10 mg/ml) were added to a static system in which soluble Ab effects would be negated. Additionally, 3D6 was efficacious when administered in a prevention paradigm, a scenario that would precede the establishment of high concentrations of soluble monomer associated with plaque and indeed a paradigm that previous reports (Das et al., 2003) have suggested may not primarily involve a phagocytic mechanism.
Previous studies have demonstrated that treatment of aged APP transgenic mice with certain anti-Ab N-terminal and C-terminal antibodies will lead to an increase in CAA-related microhemorrhage (Pfeifer et al., 2002; Racke et al., 2005; Wilcock et al., 2004) . The microhemorrhage liability first observed preclinically in transgenic mice has translated into the clinic for both active immunization (Boche et al., 2008) and passive immunization with the N-terminal antibodies bapineuzumab and gantenerumab (Black et al., 2010; Ostrowitzki et al., 2012; Sperling et al., 2011) . The clinical manifestation of microhemorrhage appears to be linked with another vascular abnormality, vasogenic edema (Sperling et al., 2011) . Although the mechanism underlying this potential adverse event is unclear, two nonmutually exclusive hypotheses have been proposed based upon the transgenic mouse studies: the redistribution of Ab into the cerebral blood vessels (Wilcock et al., 2004) or the direct binding of antibodies to existing CAA (Racke et al., 2005) . Biochemical and histological analyses have demonstrated that Ab p3-42 is a constituent of CAA in both AD patients and aged PDAPP mice (data not shown). Our studies demonstrated that the Ab p3-x antibodies did not exacerbate microhemorrhage yet were able to significantly remove existing plaque. Strikingly, the 3D6 antibody induced a clear increase in microhemorrhage; however, the antibody did not remove plaque. These results seem to be at odds with the expectation that removal of existing plaque and increased microhemorrhage are mechanistically linked. The current anti-Ab p3-x results clearly demonstrate that plaque can be removed without this adverse event. The question then becomes how does 3D6 increase microhemorrhage?
We propose that the mechanism responsible for the microhemorrhage event is dependent upon antibody binding specificity and affinity toward its epitope (Figure 7) . The 3D6 antibody has low nanomolar binding affinities toward both soluble and insoluble Ab and the antibody has a fairly fast off rate in vivo (dissociation half-life $15 min). As our in vivo target engagement data suggest, 3D6 probably becomes saturated as it enters the cloud of Ab surrounding the plaque. Since there is no physical tethering to keep the antibody:Ab complex in place, the complex moves away from the plaque by interstitial fluid dynamics. Due to the off rate, the antibody releases the Ab peptide, where it then begins to deposit along the vasculature as cerebral amyloid angi- Cartoon model that summarizes the important mechanistic insights for plaque-derived soluble equilibriums' effect on Ab immunotherapy. The cartoon depicts two different physiological situations in brain, the presence of low (A) or high (B-D) plaque loads, which are thought to represent the very earliest phase of AD (10 years prior to diagnosis) and AD at first diagnosis, respectively. (A) In the earliest phase of disease, an antibody that binds both soluble and insoluble Ab will probably be efficacious as it may engage the sparsely deposited plaque and lead to its removal (prevention). Conversely, these antibodies may also act through the direct binding to soluble Ab, either monomer or oligomeric complexes within the CNS, to facilitate the prevention or elimination of amyloid-promoting Ab seeds. During this early phase, an antibody that specifically targets plaque will only be effective at preventing and removing deposited Ab if its epitope is present at a sufficient level. (B) During stages of the disease in which extensive plaque deposition has already occurred, an antibody that binds both soluble and insoluble Ab will probably be ineffective at lowering pre-existing plaque due to limited target binding (i.e., becomes saturated with soluble Ab). (C) Additionally, if the soluble binding antibody is of weak affinity, it may result in redistribution of soluble Ab into the vasculature as CAA. (D) Lastly, an antibody that is plaque specific will probably be highly efficacious at removing existing plaque due to the high levels of target engagement.
opathy. Thus, 3D6 is likely to redistribute the soluble Ab from the cloud surrounding plaque to the vasculature with a resulting increase in CAA. Previous studies have demonstrated significant positive correlations between the amount of vascular CAA and microhemorrhage in transgenic mice and humans (Winkler et al., 2001; Yates et al., 2011) . Additionally, autopsy results from the active vaccination studies in AD patients have shown a dramatic increase of CAA in areas of the brain that had significant plaque removal (Boche et al., 2008) . The characterization of antibodies generated by active vaccination has shown that the majority of antibodies produced by the polyclonal response are of low affinity and directed against the N-terminus of Ab (Lee et al., 2005) . Other monoclonal antibodies in addition to bapineuzumab currently being tested in the clinic support this hypothesis: an antibody that binds very weakly to soluble Ab has presented with a similar microhemorrhage liability (Ostrowitzki et al., 2012) , whereas several other antibodies that bind strongly to soluble Ab appear to lack the adverse event (Adolfsson et al., 2012; Farlow et al., 2012; La Porte et al., 2011) .
Our results have significant implications for the clinical development of N-terminal nonplaque-selective antibodies.
Anti-Ab p3-42 Antibody for Alzheimer's Disease
The proposed mechanism of action for the N-terminal antibodies was based upon preclinical studies in transgenic mice and, as such, their respective clinical implementation has been modeled upon the phagocytosis mechanism, maximal effector function, and studies performed in patients with extensive deposition. A small neuroimaging study performed with the PET ligand PIB did report a significant amyloid reduction ($25%) in patients receiving the monoclonal antibody bapineuzumab as compared to placebo controls (Rinne et al., 2010) . It is important to highlight that $17% of the perceived amyloid reduction was due to an atypical rise in the PIB signature in the small (n = 7) placebo cohort (Ossenkoppele et al., 2012) . We demonstrate that N-terminal antibodies that bind both soluble and insoluble Ab fail to lower existing Ab deposition in our preclinical PDAPP transgenic model in line with previous reports in the literature. Many studies have demonstrated that N-terminal Ab antibodies prevent plaque deposition (Bard et al., 2000; Schenk et al., 1999; Schroeter et al., 2008) including studies in FcRg knockout mice (Das et al., 2003) . These, along with our current results, suggest that it is unlikely that plaque prevention is due to phagocytosis. A more plausible mechanism for N-terminal Ab antibodies would be their direct binding to soluble Ab, either monomer or oligomeric complexes within the CNS, to facilitate the prevention or elimination of amyloid-promoting Ab seeds. The anti-seeding and spreading mechanism would not be dependent upon effector function and thus if correct should enable the generation of a safer therapeutic antibody. This strategy is already being clinically implemented with MABT5102A, also known as Roche's Crenezumab, a humanized N-terminal Ab antibody engineered as a minimal effector function IgG4 (Adolfsson et al., 2012) . Indeed, testing multiple humanized anti-Ab antibodies that target different mechanisms of action in the clinic (mono or combination therapy) will be important for the field, especially as clinicians begin investigating the presymptomatic populations.
In summary, these studies have demonstrated that the development of plaque-specific Ab p3-x antibodies that lack binding to soluble Ab peptides leads to significant engagement of Ab deposits (i.e., plaque binding) and to the subsequent removal of existing plaque without a microhemorrhage liability. The separation of microhemorrhage from the plaque removal event suggests a possible redistribution mechanism of soluble Ab to the vasculature may be responsible for the adverse event. These mechanistic insights lay the foundation for the generation and engineering of safe and highly efficacious Ab antibodies for the removal of existing plaque in Alzheimer's patients. This is an important goal since biochemical and neuroimaging data demonstrate the presence of extensive plaque deposition in AD patients some 10 years prior to first memory complaint (Jack et al., 2010; Morris and Price, 2001; Price et al., 2009) and indeed by the time of diagnosis, plaque deposition is already reported to be at or near maximal levels.
EXPERIMENTAL PROCEDURES Transgenic Mice
Multiple colonies of PDAPP mice were utilized for the current studies. PDAPP line 1683 heterozygous for the APP V717F transgene was maintained on a mixed outbred background as previously described (Johnson-Wood et al., 1997).
The phenotype of the PDAPP line 1683 colony began to change wherein plaque deposition initiated at later ages, and there was a dramatic increase in the variability of deposited Ab in middle-aged mice (8-14 months old). A new PDAPP colony (line 6042) was established through an inbreeding exercise wherein mice were inbred from selected litters that maintained decreased variability in both soluble and insoluble Ab. The plaque deposition phenotype of the inbred PDAPP line 6042 was similar to the originally described PDAPP colony (Games et al., 1995) . All experiments were performed in accordance with the Institutional Animal Care and Use Guidelines for Eli Lilly.
Phagocytosis Model
Frozen brain tissue of an AD patient was embedded in M-1 Embedding Matrix at À20 C, sectioned to 20 mm, mounted on poly-D-lysine-coated cover glass (15 mm), and placed in 24-well tissue culture plates. Sixty four consecutive sections were positioned in the same order as sectioned and were incubated with or without antibodies (10 mg/ml, 500 ml, 1 hr, room temperature). The control IgG utilized in the experiment was balanced with the 3D6 effector function (i.e., IgG2b); experiments performed with control IgG1 or IgG2a result in very similar values (data not shown). Primary murine microglia (8 3 10 5 cells, 500 ml) were then added to sections and incubated for 24 hr at 37 C. Each section with antibody treatment was followed by an untreated sister section. At the end of incubation, media were removed and tissue sections and cells were homogenized with 5.2 M guanidine buffer (300 ml), diluted 103 and 1003 with PBS buffer containing 0.5 M guanidine, 0.05% Tween20 and 0.25% casein, and Ab1-42 concentration quantified by ELISA. To account for differences in the amount of deposited Ab in different sections, we normalized each unknown treatment by the untreated sister section. Data were directly plotted in GraphPad Prism and analyzed by one-way ANOVA with Newman-Keuls posttest.
Histology Ex Vivo
To evaluate the relative amount of deposited full-length Ab and N3pGlu peptide in PDAPP, cryostat serial coronal sections (10 mm thick) from a 24-month-old PDAPP mouse were incubated with 10 mg/ml of biotinylated murine antibodies 3D6 (anti-Ab 1-x ), mE8 (anti-Ab p3-x ), or negative control murine IgG. Ex vivo histological analyses of deposited Ab in AD brain was investigated on cryostat serial sections (20 mm thick) incubated with 3 mg/ml of the biotinylated murine antibodies. Secondary HRP reagents specific for biotin were employed and the deposited plaque was visualized with DAB-Plus (DAKO). Brain sections from PDAPP or AD incubated with control biotinylated murine IgG were devoid of staining (data not shown).
Histology In Vivo Target Engagement
The acute target engagement of biotinylated 3D6, mE8, or control murine IgG were evaluated in 24-to 29-month-old PDAPP mice (line 6042, homozygous). Aged PDAPP mice (n = 4 per treatment) were injected intraperitoneally with 40 mg/kg of antibody and, 72 hr later, the brains were harvested for immunohistochemistry. For subchronic injection studies with the biotinylated antibodies, 16-to 19-month-old PDAPP mice (line 6042, homozygous) were injected intraperitoneally weekly with 40 mg/kg of each antibody for four doses and the animals (n = 4 per treatment) were sacrificed 3 days after the final injection. At the conclusion of either study, mice were perfused with heparinized saline and the brain was flash frozen for histology. Cryostat serial coronal sections (12 mm thick) were stained with Dako streptavidin HRP followed by DAB plus reagent to visualize the murine biotinylated antibody that had crossed the blood-brain barrier and engaged the deposited plaque. To quantify the total area of hippocampus and cortex occupied by either antibody, we injected 19-to 22-month-old PDAPP (line 6042, homozygous) mice intraperitoneally with 40 mg/kg of either antibody (n = 6) and, 72 hr later, the animals were sacrificed and the amount of in vivo target engagement was measured (as described above). Brain sections were also immunostained with exogenous biotinylated 3D6 or mE8 in order to determine the total amount of deposited full-length Ab or Ab p3-x , respectively. The total area immunostained with the exogenous antibodies represents the total area of target possible in each section that the antibody in vivo could have bound; thus, the in vivo target engagement area was normalized to the total amount of target possible for either antibody.
In Vivo Ab-Lowering Experiments
The detailed protocols for the design and analysis of the chronic Ab-lowering studies in PDAPP transgenic mice are found in the Supplemental Experimental Procedures.
Statistics
Statistical analyses were performed using the Prism GraphPad software unless noted otherwise. For most studies, the one-way ANOVA was used to determine the significance (p values) for multiple cohort studies (>2).
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experimental Procedures and can be found with this article online at http://dx.doi. org/10.1016/j.neuron.2012.10.029.
